Exicure, Inc.

NasdaqCM XCUR

Exicure, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2024

Exicure, Inc. EBITDA is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA means earnings before interest, taxes, depreciation, and amortization, which measures a company's operating performance by excluding non-operating expenses.

Exicure, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -32.14 M.
Exicure, Inc. EBITDA for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -20.91 M, a -6.27% change year over year.

Key data

Date	EBITDA	Net Income	EPS (Diluted)	Shares (Diluted, Weighted)

NasdaqCM: XCUR

Exicure, Inc.

CEO	Mr. Paul Kang
IPO Date	May 22, 2018
Location	United States
Headquarters	2430 North Halsted Street
Employees	5
Sector	Health Care
Industries Biotechnology Pharmaceuticals

Description

Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

Key trends

Past 5 years